Rituximab for the treatment of acute refractory ITP

Sei Gyung Kim, Donna Whyte, Farzana D. Pashankar

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Most children with acute immune thrombocytopenic purpura (ITP) respond to first-line therapies including intravenous immunoglobulin, corticosteroids, and Rho(D) immune globulin. However, there is no clear consensus regarding second-line therapies for the treatment of ITP, not responding to first-line therapies in the acute setting. Adapting from the chronic ITP literature, 3 patients with acute refractory ITP were treated with intravenous rituximab and showed immediate and sustained remission. Combined therapy that includes rituximab may be an effective regimen for acute refractory ITP.

Original languageEnglish (US)
Pages (from-to)e149-e151
JournalJournal of Pediatric Hematology/Oncology
Issue number3
StatePublished - Apr 2014
Externally publishedYes


  • Acute immune thrombocytopenic purpura
  • children
  • rituximab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Rituximab for the treatment of acute refractory ITP'. Together they form a unique fingerprint.

Cite this